In one aspect, the disclosure relates to nanoparticle compositions including TT-10 or a pharmaceutically acceptable salt thereof and nanoparticles including at least one biocompatible polymer or copolymer such as poly-lactic-co-glycolic acid. Also disclosed are methods for improving at least one cardiac function or property following heart damage in a subject, the methods including at least the step of administering the nanoparticle compositions to the subject. In another aspect, the nanoparticle compositions can be administered by intraperitoneal injection and are active at a target site for a period of at least 4 weeks.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.

A co-drug according to Formula (I) or Formula (II) is provided,
R—X—NH—CO—CO—OR.sup.1  (I)
R—X—CO—O—CH.sub.2—CO—OR.sup.1  (II)
wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR.sup.1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR.sup.1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.

Provided herein are multi-functional particles. The particles may include poly(lactide-co-glycolide)-g-polyethylenimine (PLGA-g-PEI (PgP)), at least one targeting moiety, at least one therapeutic agent, and/or at least one nucleic acid. Also provided herein are methods of using the multi-functional particles.

An implant device includes a polymer tube including an enclosed inner space, and a mixture of a hydrogel and a plurality of nanoparticles within the enclosed inner space. Each of the plurality of nanoparticles includes a shell, payload within the shell, and one or more photothermal agents on a surface of the shell. A wall of the polymer tube includes one or more layers of nanoporous polymer sheets including a plurality of pores. The dimension of the nanoparticles is greater than the dimension of the pores, and the dimension of the payload is smaller than the dimension of the pores.

A delivery system for delivering water-soluble components and water-insoluble components of whole-cell components using nano-sized or micro-sized particles, and a use of which in preparing vaccines for preventing and treating cancer. The whole-cell components delivery system consisting of a nano-sized or micron-sized particle and whole-cell components loaded on the particle, the whole-cell components are water-soluble components and water-insoluble components of a whole cell in a cell or tissue. The mutated proteins or peptides produced by cancer in cellular components are loaded on nanoparticles or micronparticles. These immunogenic substances generated by mutations in disease in whole-cell components can be used for cancer prevention and treatment and preparing vaccines for preventing and/or treating cancer.

The present invention relates to an active substance delivery system, preferably an anti-cancer agent delivery system, for use in the treatment of cancer in a human subject, comprising one or more anti-cancer agents and optionally further active substances, both included in nano- and/or microparticles, and a method for producing such a delivery system.

The present disclosure encompasses pharmaceutical composition, kits and methods for enhancing therapeutic compliance.

Provided herein are erythrocytes with polymeric particles (i.e., ‘backpacks’) adhered that provide delivery of payload therapeutic agents to subjects administered these cells.